Immunoglobulin G1-kappa, anti-[Homo sapiens CLDN18 (SFTPJ, surfactant associated protein J) isoform 2, extracellular domain 1 (EC1)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-448) [VH (Homo sapiens IGHV1-46*01 (87.8%) -(IGHD) -IGHJ4*01 (92.9%) L123>T (113), CDR-IMGT [8.8.11] (26-33.51-58.97-107)) (1-118) -Homo sapiens IGHG1*01 (100%), G1m17,1 (CH1 K120 (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfide with kappa light chain humanized (1'-220') [VKAPPA (Homo sapiens IGKV4-1*01 (91.1%) - IGKJ4*01 (100%), CDR-IMGT [12.3.9] (27-38.56-58.95-103)) (1'-113') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (159), V101 (197) (114'-220')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1 lacking the glutamine synthetase (GS-KO) gene, glycoform alfa
Gastroesophageal-junction Cancer
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
112 Active assets in the Gastroesophageal-junction Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan AstraZeneca | Phase 3 | BBB |
Cyclophosphamide Beijing Biotech | Phase 3 | BB |
Pembrolizumab Eikon Therapeutics | Phase 3 | BB |
FLUOROURACILUM Alliance for Clinical Trials in Oncology | Phase 3 | BB |
Eloxatin Alliance for Clinical Trials in Oncology | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Immunoglobulin G1-kappa, anti-[Homo sapiens CLDN18 (SFTPJ, surfactant associated protein J) isoform 2, extracellular domain 1 (EC1)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-448) [VH (Homo sapiens IGHV1-46*01 (87.8%) -(IGHD) -IGHJ4*01 (92.9%) L123>T (113), CDR-IMGT [8.8.11] (26-33.51-58.97-107)) (1-118) -Homo sapiens IGHG1*01 (100%), G1m17,1 (CH1 K120 (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfide with kappa light chain humanized (1'-220') [VKAPPA (Homo sapiens IGKV4-1*01 (91.1%) - IGKJ4*01 (100%), CDR-IMGT [12.3.9] (27-38.56-58.95-103)) (1'-113') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (159), V101 (197) (114'-220')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1 lacking the glutamine synthetase (GS-KO) gene, glycoform alfa is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →